Quick Links

Breadcrumbs Navigation

Home > Clinical Trials > Adult Clinical Trials - New Anti-Cancer Drugs (Phase I)

Jumbo Large Regular Text:

Adult Clinical Trials - New Anti-Cancer Drugs (Phase I)

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact giclintrials@duke.edu or contact Shawna Savage, RN or Liz Anderson, RN at 919-684-6342.

Items 1 - 13 of 13

A Phase I, Open Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Properties of Orally Administered AT-406 in Patients With Advanced Solid Tumors and Lymphoma
Principal Investigator: Herbert Hurwitz
Phase: Phase I
Phone: 919-684-6342

An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with Other Anticancer Treatment in Patients with Solid Tumors
Principal Investigator: Herbert Hurwitz
Phase: Phase I
Phone: 919-684-6342

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects with Advanced Malignancies
Principal Investigator: Herbert Hurwitz
Phase: Phase I
Phone: 919-684-6342

Phase I Dose Escalation of Pazopanib plus TH-302 in Advanced Solid Tumors
Principal Investigator: Herbert Hurwitz
Phase: Phase I
Phone: 919-684-6342

A Phase IV, Placebo-Controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients with Advanced Cancer
Principal Investigator: Herbert Hurwitz
Phase: Phase IV
Phone: 919-684-6342

AREN0321 Treatment of High Risk Renal Tumors
Principal Investigator: Susan Kreissman
Phase: N/A
Phone: 919-684-3401

NANT2008-02 A Phase 1 Study of Vorinostat in Combination with 13-cis-retinoic acid in Patients with Refractory/Recurrent Neuroblastoma (IND#79176)
Principal Investigator: Susan Kreissman
Phase: Phase I
Phone: 919-684-3401

A PHASE I STUDY TO EVALUATE THE ANTITUMOR ACTIVITY AND SAFETY OF DUKE-002-VRP(HUHER2-ECD+TM), AN ALPHAVIRAL VECTOR ENCODING THE HER2 EXTRACELLULAR DOMAIN AND TRANSMEMBRANE REGION, IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCERS INCLUDING BREAST CANCER
Principal Investigator: Michael Morse
Phase: Phase I
Phone: 919-684-6342

A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults with Gastrointestinal Adenocarcinomas
Principal Investigator: Michael Morse
Phase: Phase I
Phone: 919-684-6342

A multi-center, open-label study to assess pharmacokinetics of TKI258 in adult cancer patients with normal and impaired hepatic function
Principal Investigator: Fatima Rangwala
Phase: Phase I
Phone: 919-684-6342

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-700, a Monoclonal Anitbody, in Subjects with Advanced Solid Tumors
Principal Investigator: John Strickler
Phase: Phase I
Phone: 919-668-1462

A PHASE I, OPEN-LABEL, SINGLE-SEQUENCE CROSSOVER STUDY ASSESSING THE EFFECT OF TIVANTINIB (ARQ197) ON THE PHARMACOKINETICS OF OMEPRAZOLE/S-WARFARIN/CAFFEINE/MIDAZOLAM AND DIGOXIN IN CANCER SUBJECTS
Principal Investigator: John Strickler
Phase: Phase I
Phone: 919-684-6342

A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 780 in Adult Subjects with Advanced Solid Tumors
Principal Investigator: Gordana Vlahovic
Phase: Phase I
Phone: 919-684-6342